ES2804424T3 - Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre - Google Patents

Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre Download PDF

Info

Publication number
ES2804424T3
ES2804424T3 ES07796769T ES07796769T ES2804424T3 ES 2804424 T3 ES2804424 T3 ES 2804424T3 ES 07796769 T ES07796769 T ES 07796769T ES 07796769 T ES07796769 T ES 07796769T ES 2804424 T3 ES2804424 T3 ES 2804424T3
Authority
ES
Spain
Prior art keywords
peptide
stroke
treatment
fever
animals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07796769T
Other languages
English (en)
Spanish (es)
Inventor
Michael Tymianski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NoNO Inc
Original Assignee
NoNO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NoNO Inc filed Critical NoNO Inc
Application granted granted Critical
Publication of ES2804424T3 publication Critical patent/ES2804424T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
ES07796769T 2006-07-11 2007-07-10 Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre Active ES2804424T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83018906P 2006-07-11 2006-07-11
US83357206P 2006-07-26 2006-07-26
PCT/US2007/015747 WO2008008348A2 (en) 2006-07-11 2007-07-10 Method and compositions for treating stroke with fever

Publications (1)

Publication Number Publication Date
ES2804424T3 true ES2804424T3 (es) 2021-02-08

Family

ID=38923841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07796769T Active ES2804424T3 (es) 2006-07-11 2007-07-10 Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre

Country Status (7)

Country Link
US (2) US8685925B2 (enExample)
EP (1) EP2043671B1 (enExample)
JP (2) JP5746468B2 (enExample)
CA (1) CA2657665C (enExample)
DK (1) DK2043671T3 (enExample)
ES (1) ES2804424T3 (enExample)
WO (1) WO2008008348A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) * 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
WO2010004003A2 (en) * 2008-07-09 2010-01-14 University Of Copenhagen Modified peptides as potent inhibitors of the psd-95/nmda receptor interaction
SMT202000056T1 (it) * 2009-06-10 2020-03-13 Nono Inc Co-somministrazione di un agente legato ad un peptide di internalizzazione tat con un inibitore di degranulazione dei mastociti
DK2440230T3 (da) 2009-06-10 2021-01-18 Nono Inc Behandlingsregimener til behandling af neurologisk sygdom
CN103533949B (zh) * 2011-05-13 2015-11-25 哥本哈根大学 作为缺血性脑损伤的有效神经保护剂并用于治疗疼痛的psd-95的高亲和力的二聚抑制剂
MX339993B (es) 2011-05-13 2016-06-21 Københavns Univ (University Of Copenhagen) Inhibidores dimericos de alta afinidad de psd-95 como neuroprotectores eficientes contra daño isquemico cerebral y para el tratamiento de dolor.
KR20220106862A (ko) 2011-06-24 2022-07-29 노노 인코포레이티드 허혈에 대한 psd-95 억제제와의 조합 요법
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
US9680916B2 (en) 2013-08-01 2017-06-13 Flowtraq, Inc. Methods and systems for distribution and retrieval of network traffic records
AU2016348632B2 (en) * 2015-11-06 2023-07-13 The Board Of Trustees Of The University Of Illinois Peptides and method for treatment of cardiac arrest
AU2017422458B2 (en) * 2017-07-05 2021-07-15 Biocells (Beijing) Biotech Co., Ltd. Polypeptide pharmaceutically acceptable salt et use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US7510824B2 (en) * 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
EP1578365A4 (en) 2002-11-14 2009-09-23 Arbor Vita Corp MOLECULAR INTERACTIONS IN NEURONS
WO2005061548A1 (en) * 2003-12-23 2005-07-07 Nono Inc. Polypeptides for modulating binding of trp channel proteins and trp-associated proteins.
EP1884521A1 (en) * 2006-07-31 2008-02-06 Xigen S.A. Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins
DK2120987T3 (en) * 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
US8080518B2 (en) * 2007-12-05 2011-12-20 Arbor Vita Corporation Co-administration of an agent linked to an internalization peptide with an anti-inflammatory

Also Published As

Publication number Publication date
EP2043671B1 (en) 2020-05-20
EP2043671A4 (en) 2010-09-15
US8685925B2 (en) 2014-04-01
CA2657665A1 (en) 2008-01-17
WO2008008348A3 (en) 2008-06-12
WO2008008348A2 (en) 2008-01-17
US20120208764A1 (en) 2012-08-16
CA2657665C (en) 2015-06-02
EP2043671A2 (en) 2009-04-08
JP2009544585A (ja) 2009-12-17
JP2013151495A (ja) 2013-08-08
JP5746468B2 (ja) 2015-07-08
DK2043671T3 (da) 2020-06-15
JP6088272B2 (ja) 2017-03-01
US20140323406A1 (en) 2014-10-30

Similar Documents

Publication Publication Date Title
ES2804424T3 (es) Péptido y composición del mismo para usar en el tratamiento del accidente cerebrovascular con fiebre
ES2446292T3 (es) Tratamiento del accidente cerebrovascular y otras enfermedades sin inhibir los canales de calcio de tipo N
ES2847293T3 (es) Regímenes de tratamiento para el tratamiento de enfermedades neurológicas
EP2175873B1 (en) Peptide inhibitors of nmda receptor for use in treating anxiety disorders
BRPI0820912B1 (pt) Uso de um agente farmacológico ligado a um peptídeo tat, uso de um inibidor de degranulação de mastócito ou anti-histamínico e kit compreendendo um agente farmacológico
ES2446306T3 (es) Uso de un inhibidor de psd-95 tratamiento para la epilepsia
ES2765281T3 (es) Coadministración de un agente unido a un péptido de interiorización con un agente antiinflamatorio
Wang et al. Trans-activator of transcription-mediated delivery of NEP1-40 protein into brain has a neuroprotective effect against focal cerebral ischemic injury via inhibition of neuronal apoptosis
US12473332B2 (en) Modified peptides and associated methods of use
BR112020000115A2 (pt) sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
ES2617309T3 (es) Métodos y ensayos de tratamiento de sujetos con eliminación, mutación o expresión reducida de SHANK3
WO2017185249A1 (zh) 兴奋性神经毒性相关损伤的治疗肽
Edwards et al. Assessment of therapeutic window for poly‐arginine‐18D (R18D) in a P7 rat model of perinatal hypoxic‐ischaemic encephalopathy
KR20070103009A (ko) 뇌혈류를 증가시키는 방법
US10751324B2 (en) Treatment of TNF- alpha cytotoxicity
Doyle Development of novel therapeutics for stroke: preclinical investigations of osteopontin and 3-iodothyronamine.
US20090075898A1 (en) Complement C3A Derived Peptides and Uses Thereof